marked.bio

CLDN18.2 ADC · ADC

SHR-A1904

5 active trials, targeting Claudin 18.2. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
Claudin 18.2 expression 5 5 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of SHR-A1904.

  1. Jiangsu Hengrui 4

Trials

5 of 5 trials shown

  1. SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Recruiting Phase 3 Jiangsu Hengrui Started 2024Primary completion 2027-09 NCT06649292

    SHR-A1904paclitaxeldocetaxelirinotecan

    6. positive CLDN18.2 expression in tumor tissue;

    Claudin 18.2 expressionSecond-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  2. A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

    Recruiting Phase 2 Jiangsu Hengrui Started 2026Primary completion 2030-12 NCT07450976

    SHR-A1904

    CLDN18.2 positive expression;

    Claudin 18.2 expressionBiliary Tract Cancer

  3. Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

    Not yet recruiting Phase 2 China Medical University Started 2025Primary completion 2029-08 NCT06881017

    trastuzumabadebrelimabapatinibS-1capecitabineoxaliplatinzolbetuximab FDA EUtrastuzumab rezetecanSHR-A1904SHR-1701

    Archival or fresh tumor tissue sample available for biomarker testing (HER2, CLDN18.2, and PD-L1 expression);

    Claudin 18.2 expressionGastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive

  4. A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

    Recruiting Phase 1/2 Jiangsu Hengrui Started 2022Primary completion 2026-05 NCT05277168

    SHR-A1904

    Positive expression of Claudin 18.2 (\>= 50% of cells with 2+ or 3+ expression, either from fresh or archival tissue) is requ…

    Claudin 18.2 expressionAdvanced Solid Tumors

  5. SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

    Recruiting Phase 1 Jiangsu Hengrui Started 2024Primary completion 2027-12 NCT06350006

    SHR-A1904adebrelimabCAPOX

    6. positive CLDN18.2 expression in tumor tissue;

    Claudin 18.2 expressionCLDN18.2-positive Advanced Solid Tumor